SLDB
Price
$6.29
Change
+$0.10 (+1.62%)
Updated
Aug 8 closing price
Capitalization
487.57M
XNCR
Price
$7.25
Change
+$0.02 (+0.28%)
Updated
Aug 11, 11:10 AM (EDT)
Capitalization
515.67M
91 days until earnings call
Interact to see
Advertisement

SLDB vs XNCR

Header iconSLDB vs XNCR Comparison
Open Charts SLDB vs XNCRBanner chart's image
Solid Biosciences
Price$6.29
Change+$0.10 (+1.62%)
Volume$1.13M
Capitalization487.57M
Xencor
Price$7.25
Change+$0.02 (+0.28%)
Volume$100
Capitalization515.67M
SLDB vs XNCR Comparison Chart in %
Loading...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SLDB vs. XNCR commentary
Aug 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SLDB is a Hold and XNCR is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 11, 2025
Stock price -- (SLDB: $6.29 vs. XNCR: $7.23)
Brand notoriety: SLDB and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SLDB: 68% vs. XNCR: 126%
Market capitalization -- SLDB: $487.57M vs. XNCR: $515.67M
SLDB [@Biotechnology] is valued at $487.57M. XNCR’s [@Biotechnology] market capitalization is $515.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SLDB’s FA Score shows that 2 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • SLDB’s FA Score: 2 green, 3 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, SLDB is a better buy in the long-term than XNCR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SLDB’s TA Score shows that 4 TA indicator(s) are bullish while XNCR’s TA Score has 5 bullish TA indicator(s).

  • SLDB’s TA Score: 4 bullish, 5 bearish.
  • XNCR’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, XNCR is a better buy in the short-term than SLDB.

Price Growth

SLDB (@Biotechnology) experienced а -7.91% price change this week, while XNCR (@Biotechnology) price change was -9.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +22.40%. For the same industry, the average monthly price growth was +31.92%, and the average quarterly price growth was +19.43%.

Reported Earning Dates

XNCR is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+22.40% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XNCR($516M) has a higher market cap than SLDB($488M). SLDB YTD gains are higher at: 57.250 vs. XNCR (-68.538). SLDB has higher annual earnings (EBITDA): -136.83M vs. XNCR (-161.68M). XNCR has more cash in the bank: 470M vs. SLDB (307M). SLDB has less debt than XNCR: SLDB (23.6M) vs XNCR (67.8M). XNCR has higher revenues than SLDB: XNCR (127M) vs SLDB (0).
SLDBXNCRSLDB / XNCR
Capitalization488M516M95%
EBITDA-136.83M-161.68M85%
Gain YTD57.250-68.538-84%
P/E RatioN/AN/A-
Revenue0127M-
Total Cash307M470M65%
Total Debt23.6M67.8M35%
FUNDAMENTALS RATINGS
SLDB vs XNCR: Fundamental Ratings
SLDB
XNCR
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
78
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
3692
P/E GROWTH RATING
1..100
35
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (25) in the Biotechnology industry is somewhat better than the same rating for XNCR (78). This means that SLDB’s stock grew somewhat faster than XNCR’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as XNCR (100). This means that SLDB’s stock grew similarly to XNCR’s over the last 12 months.

SLDB's SMR Rating (97) in the Biotechnology industry is in the same range as XNCR (97). This means that SLDB’s stock grew similarly to XNCR’s over the last 12 months.

SLDB's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for XNCR (92). This means that SLDB’s stock grew somewhat faster than XNCR’s over the last 12 months.

SLDB's P/E Growth Rating (3) in the Biotechnology industry is in the same range as XNCR (5). This means that SLDB’s stock grew similarly to XNCR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SLDBXNCR
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
69%
Bullish Trend 4 days ago
68%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
84%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
85%
Advances
ODDS (%)
Bullish Trend 14 days ago
80%
Bullish Trend 20 days ago
72%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 4 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
71%
Aroon
ODDS (%)
Bullish Trend 4 days ago
88%
Bullish Trend 4 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ITHAX44.250.29
+0.66%
Hartford Capital Appreciation A
ASYLX15.720.07
+0.45%
AB Select US Long/Short Advisor
MAIJX19.450.01
+0.05%
Morgan Stanley Inst Passport ovrs eq R6
MMGEX9.06-0.05
-0.55%
MassMutual Small Cap Gr Eq A
UBPIX15.95-0.22
-1.36%
ProFunds UltraLatin America Inv

SLDB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with BEAM. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLDB
1D Price
Change %
SLDB100%
+1.62%
BEAM - SLDB
48%
Loosely correlated
-1.34%
EDIT - SLDB
46%
Loosely correlated
-11.24%
ALLO - SLDB
45%
Loosely correlated
-0.95%
XNCR - SLDB
43%
Loosely correlated
-1.23%
NTLA - SLDB
43%
Loosely correlated
-5.85%
More

XNCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with CRNX. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XNCR
1D Price
Change %
XNCR100%
-1.23%
CRNX - XNCR
60%
Loosely correlated
-3.69%
SYRE - XNCR
57%
Loosely correlated
N/A
BEAM - XNCR
57%
Loosely correlated
-1.34%
CGON - XNCR
54%
Loosely correlated
+2.05%
MGNX - XNCR
54%
Loosely correlated
-4.35%
More